AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33727659
Drug: 0.02% fluorometholone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.02% fluorometholone ophthalmic suspension
Trial: 34252034
Drug: Standard operation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard operation preparation procedure
Trial: 36988361
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine (ITM) 0.3 mg
Trial: 32606097
Drug: Chemotherapy (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + atezolizumab
Trial: 32606097
Drug: Chemotherapy (paclitaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (paclitaxel weekly or pegylated liposomal doxorubicin) + bevacizumab + placebo
Trial: 33802559
Drug: Progressive dynamic
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive dynamic balance training (PDBT) with physical therapy
Trial: 32976938
Drug: Pembrolizumab (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (200 mg/Q3W)
Trial: 32976938
Drug: Single-agent chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent chemotherapy (gemcitabine or vinorelbine)
Trial: 33319755
Drug: Early pregnancy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early pregnancy treatment (nutrition counseling, glucose monitoring, medications as needed)
Trial: 33067279
Drug: Sulforaphane treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulforaphane treatment for 12 weeks
Trial: 33067279
Drug: Sulforaphane treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulforaphane treatment
Trial: 33006504
Drug: Ethanolic extract
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ethanolic extract of Opuntia ficus-indica var. saboten (OFE) administered for 12 weeks
Trial: 32737350
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with LCPUFA (docosahexaenoic acid 300 mg/day, eicosapentaenoic acid 100 mg/day, arachidonic acid 120 mg/day)
Trial: 33415379
Drug: Platelet-rich fibrin
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich fibrin (PRF) injection (1-mL)
Trial: 33415379
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide (TA) injection (0.5-mL)
Trial: 33883048
Drug: Physiological saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiological saline oral care
Trial: 36067479
Drug: Dehydrated human
RxNorm normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dehydrated human amnion and chorion allograft (dHACA) plus standard of care (weekly and biweekly applications)
Trial: 33617972
Drug: Supplement combination
RxNorm normalized name: dietary supplement combination no.28
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplement combination (Boswellia serrata extract 250 mg/day, pine bark extract 100 mg/day, methylsulfonylmethane 1,500 mg/day, curcumin 168 mg/day)
Trial: 33484397
Drug: Parent-delivered therapy
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent-delivered therapy (5-week duration)
Trial: 33678535
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive pill (OCP condition)
Trial: 34319998
Drug: Prophylactic anticoagulants
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic anticoagulants (PAC)
Trial: 34319998
Drug: No prophylactic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No prophylactic anticoagulants (no PAC)
Trial: 34319998
Drug: S/P-albumin <20g/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/P-albumin <20g/L
Trial: 34319998
Drug: S/P-albumin ≥20g/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S/P-albumin ≥20g/L
Trial: 33235154
Drug: Short-course induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course induction chemotherapy (2 cycles of cisplatin 20 mg/m2 plus etoposide 40 or 100 mg/m2 for 5 days) followed by low-dose radiotherapy (dose: 2340 cGy) without a tumor bed boost
Trial: 33235154
Drug: Low-dose radiotherapy
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiotherapy without a tumor bed boost
Trial: 32975835
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg LSD
Trial: 32975835
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg LSD
Trial: 32975835
Drug: 5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 µg LSD
Trial: 32975835
Drug: 5 µg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 µg, 10 µg, 20 µg LSD
Trial: 33389959
Drug: Diabetic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diabetic insulin users
Trial: 33389959
Drug: Diabetic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diabetic insulin users (male)
Trial: 33389959
Drug: Diabetic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diabetic insulin users (age 40-59)
Trial: 33389959
Drug: Diabetic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Diabetic insulin users (2 to 4 years of morbidity)
Trial: 36454874
Drug: Adolescents who
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescents who self-reported to ever having had sex and used alcohol/drugs during their last sexual encounter
Trial: 33290971
Drug: Phytosterol capsules
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol capsules (1.5 g/day)
Trial: 33290971
Drug: Sunflower oil
RxNorm normalized name: Sunflower Oil
DrugBank: Sunflower oil (DB14329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunflower oil capsules (2 g/day)
Trial: 33306985
Drug: RBD monoclonal
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBD monoclonal antibodies
Trial: 33028566
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin (20 mg/kg for 3 days, followed by 10 mg/kg for a further 7 days)
Trial: 33028566
Drug: Intravenous azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous azithromycin and placebo
Trial: 35365148
Drug: Glucose intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose intake group (75 g glucose)
Trial: 35610083
Drug: Multi-disciplinary intervention
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-disciplinary intervention including nutrition education using a smartphone game, aerobic exercise, and cognitive behavioral therapy (CBT)
Trial: 32443319
Drug: UVA/riboflavin cross-linking
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UVA/riboflavin cross-linking (0.1% riboflavin solution for 10 minutes)
Trial: 32443319
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (directly into corneal preservation solution)
Trial: 35837807
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) in AIDP subtype
Trial: 35837807
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) in AMAN subtype
Trial: 33222598
Drug: High Lp(a)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Lp(a) group (≥60 mg/dL)
Trial: 33222598
Drug: Low Lp(a)
RxNorm normalized name: LP-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Lp(a) group (<60 mg/dL)
Trial: 33638625
Drug: Fexofenadine/pseudoephedrine combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine/pseudoephedrine combination tablet (F/P)
Trial: 32822600
Drug: Nitisinone 10
RxNorm normalized name: nitisinone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitisinone 10 mg daily
Trial: 32795925
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d antofloxacin (AT)
Trial: 32795925
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d antofloxacin (AT)
Trial: 32795925
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d moxifloxacin
Trial: 33275787
Drug: Tele‐PST (problem-solving
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tele‐PST (problem-solving therapy tele-delivered by licensed clinicians)
Trial: 34526104
Drug: Kabasura Kudineer
RxNorm normalized name: Kadsura coccinea whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kabasura Kudineer (KSK) 60 mL twice daily for 7 days
Trial: 34526104
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 60,000 IU daily and zinc 100 mg daily for 7 days (Control)
Trial: 33599086
Drug: Warm humidified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warm humidified CO2 (WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 33599086
Drug: Standard procedure
RxNorm normalized name: HOMOSALATE 60 mg in 1 mL / OCTOCRYLENE 30 mg in 1 mL / ZINC OXIDE 80 mg in 1 mL TOPICAL STICK [Standard Procedure Lip Balm SPF 50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard procedure (non-WHCO2) during cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 32986087
Drug: Early introduction
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early introduction group (EIG) consuming 2.66 (1.85) g/wk of gluten from age 4 months.
Trial: 32986087
Drug: Standard introduction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard introduction group (SIG) consuming 0.49 (1.40) g/wk of gluten between ages 4 and 6 months.
Trial: 34617003
Drug: standard-dose CS
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-dose CS
Trial: 34617003
Drug: standard-dose CS
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard-dose CS plus EEN (Modulen 1.5 kcal)
Trial: 32545539
Drug: Intervention small
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention small group social networks (10 participants, 12 weekly sessions)
Trial: 34000251
Drug: Estetrol (E4)
RxNorm normalized name: estetrol
DrugBank: Estetrol (DB12235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Estetrol (E4) 15 mg and drospirenone (DRSP) 3 mg
Trial: 36075994
Drug: S1 maintenance
RxNorm normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: S1 maintenance therapy (MT)
Trial: 36075994
Drug: non-maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-maintenance therapy (non-MT)
Trial: 32929634
Drug: Elderberry extract
RxNorm normalized name: elderberry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elderberry extract (15 ml orally twice a day for 5 days for ages 5-12; 15 ml 4 times a day for 5 days for > 12 years)
Trial: 36242718
Drug: Deutetrabenazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (mean dose at week 8: 38.1 mg for Rollover; 36.5 mg for Switch)
Trial: 36242718
Drug: Deutetrabenazine (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deutetrabenazine (mean dose across cohorts after titration: 37.6 mg; final visit mean dose: 45.7 mg)
Trial: 34130688
Drug: Mistletoe extract
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe extract (Abnoba Viscum Q®) administered subcutaneously during chemoradiotherapy.
Trial: 35094827
Drug: Solution-Oriented Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution-Oriented Therapy Programme (6 to 10 sessions)
Trial: 34383607
Drug: Caffeine (5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg per kg of body mass)
Trial: 33626213
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment (0.03%) application twice/day
Trial: 33626213
Drug: Microneedling once/week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microneedling once/week and tacrolimus ointment application directly after microneedling and twice/day the rest of the week
Trial: 33626213
Drug: Tacrolimus ointment
RxNorm normalized name: Tacrolimus Ointment
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus ointment application twice/day under occlusion by polyethylene foil
Trial: 36416303
Drug: Group-Early Start
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-Early Start Denver Model (G-ESDM) in inclusive classrooms
Trial: 36416303
Drug: Group-Early Start
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group-Early Start Denver Model (G-ESDM) in specialised classrooms
Trial: 34265007
Drug: Lorcaserin 20
RxNorm normalized name: lorcaserin 20 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorcaserin 20 mg
Trial: 616616941
Drug: Transition Preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transition Preparation Training Program (TPT)
Trial: 32804345
Drug: Cholecalciferol supplementation
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol supplementation (500 UI/kg p.o. weekly)
Trial: 32688398
Drug: LIA with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LIA with steroids (triamcinolone)
Trial: 32688398
Drug: LIA without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LIA without steroids
Trial: 35068454
Drug: Plasma L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma L-carnitine
Trial: 35068454
Drug: L-carnitine addition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine addition to conventional risk factors
Trial: 35068454
Drug: Higher L-carnitine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher L-carnitine and lower inflammatory status
Trial: 37068889
Drug: Propofol total
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol total intravenous anaesthesia (TIVA)
Trial: 32604288
Drug: Bilateral regional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral regional maxillary nerve block (MNB) with 0.15 ml/kg of lidocaine clorhidrate 2% with epinephrine 1:50.000, under direct vision through the spheno palatine holes, before surgery.
Trial: 616497285
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments (fasting, rehydration, acid suppression, inhibition of pancreatic enzyme activity, use of antibiotics)
Trial: 33731586
Drug: Hemoclips monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoclips monotherapy
Trial: 33731586
Drug: Hemoclips combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoclips combination therapy
Trial: 33731586
Drug: Hemoclips combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoclips combination therapy (in antithrombotic subgroup)
Trial: 33731586
Drug: Hemoclips combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoclips combination therapy (after propensity score matching)
Trial: 32348985
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg IV ferric derisomaltose
Trial: 35028890
Drug: High Dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Dose Group (HDG) - 3750 IU VD3/day
Trial: 35028890
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose Group (LDG) - 600 IU VD3/day
Trial: 35017261
Drug: Cigarette packs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette packs with background colour and capsule image
Trial: 35017261
Drug: Cigarette packs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cigarette packs displaying a flavour name, background colour or capsule image
Trial: 35968208
Drug: Symbiotic (Pedilact)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbiotic (Pedilact) - 5 drops containing Lactobacillus reuteri and simethicone (20 mg twice daily) for 4 weeks
Trial: 35075138
Drug: Capecitabine chemotherapy
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine chemotherapy alone or in combination with bevacizumab (± mitomycin C)
Trial: 34552008
Drug: Doxorubicin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin plus palifosfamide with MRP-1 inhibitors (nilotinib or avapritinib)
Trial: 34552008
Drug: MRP-1 inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MRP-1 inhibitors (nilotinib, ripretinib, selumetinib, avapritinib)
Trial: 35110894
Drug: Ultrasound-guided PECS
RxNorm normalized name: ULTRASOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided PECS I (0.2 ml/kg) and PECS II (0.4 ml/kg) block, post-induction with 0.25% levobupivacaine, maximum dose of 2 mg/kg.
Trial: 32278103
Drug: Increased abdominal
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased abdominal pressure using a 3000 ml bag of normal saline (NS)
Trial: 34106667
Drug: No special
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No special treatment (Control group)
Trial: 35341689
Drug: Tisagenlecleucel CAR-T
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tisagenlecleucel CAR-T therapy
Trial: 34489296
Drug: Development and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Development and use of a tapering schedule
Trial: 32492138
Drug: 150 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg/d of resveratrol (n = 20)
Trial: 33248530
Drug: IPR enhanced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPR enhanced with youth- and parent-directed online Single-Session Interventions (SSIs) designed to reduce youths’ internalizing symptoms and improve parents’ mental health treatment expectancies.
Trial: 35334836
Drug: Three eggs
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three eggs per day for 4 weeks (choline equivalent of 400 mg/day)
Trial: 35334836
Drug: Choline bitartrate
RxNorm normalized name: Choline Bitartrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Choline bitartrate (CB) supplement for 4 weeks (choline equivalent of 400 mg/day)
Trial: 32936010
Drug: Letrozole (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (2.5 mg/day) combined with oral contraceptives (Desogestrel and Ethinylestradiol Tablets)
Trial: 32936010
Drug: Oral contraceptives
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptives (Desogestrel and Ethinylestradiol Tablets) alone
Trial: 34705283
Drug: Isatuximab (Isa)
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab (Isa) 10 mg/kg weekly for 4 weeks then every 2 weeks (QW-Q2W) in combination with pomalidomide/dexamethasone (Pd)
Trial: 34705283
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to a monthly dosing regimen of Isatuximab after 6 months
Trial: 34705283
Drug: Isatuximab (Isa)
RxNorm normalized name: Isatuximab
DrugBank: Isatuximab (DB14811)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Isatuximab (Isa) 10 mg/kg QW-Q2W regimen
Trial: 35866676
Drug: Mouthwash with
RxNorm normalized name: Sodium Fluoride 0.02% Oromucosal Solution [REMBRANDT WHITENING MOUTHWASH WITH FLUORIDE]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mouthwash with Sambucus williamsii var. coreana extract (5 days treatment)
Trial: 33646464
Drug: Chemotherapy of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy of physician’s choice
Trial: 33389399
Drug: CTC-oriented personalized
RxNorm normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CTC-oriented personalized adjuvant therapy (experimental group, n = 68)